HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glenn Crater Selected Research

revefenacin

10/2019Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
10/2019Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease.
4/2019Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.
1/2019Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
1/2019Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Glenn Crater Research Topics

Disease

22Chronic Obstructive Pulmonary Disease (COPD)
10/2019 - 08/2008
3Dyspnea (Shortness of Breath)
05/2014 - 10/2009
2Asthma (Bronchial Asthma)
02/2016 - 05/2014
2Inflammation (Inflammations)
02/2016 - 01/2014
1Atrial Fibrillation
01/2019
1Cardiovascular Diseases (Cardiovascular Disease)
01/2019
1Allergic Rhinitis
05/2014
1Respiratory Tract Infections (Respiratory Tract Infection)
05/2014
1Pulmonary Fibrosis (Fibrosing Alveolitis)
05/2014
1Cystic Fibrosis (Mucoviscidosis)
05/2014
1Airway Obstruction (Choking)
11/2009
1Cough
11/2009

Drug/Important Bio-Agent (IBA)

9GSK573719IBA
12/2014 - 07/2012
8Bronchodilator Agents (Bronchodilators)IBA
10/2019 - 11/2009
8Muscarinic AntagonistsIBA
10/2019 - 10/2012
6Tiotropium Bromide (Spiriva)FDA Link
10/2019 - 02/2012
5revefenacinIBA
10/2019 - 01/2019
5vilanterolIBA
12/2014 - 12/2012
4Fluticasone-Salmeterol Drug Combination (Advair)FDA Link
02/2012 - 08/2008
3Cholinergic Antagonists (Anticholinergics)IBA
01/2019 - 01/2012
3Adrenal Cortex Hormones (Corticosteroids)IBA
02/2016 - 10/2009
3Albuterol (Salbutamol)FDA LinkGeneric
05/2014 - 08/2008
3Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
07/2013 - 07/2012
1Therapeutic UsesIBA
10/2019
1SolutionsIBA
01/2019
1omega-Chloroacetophenone (Mace)IBA
01/2019
1CytokinesIBA
02/2016
1Biomarkers (Surrogate Marker)IBA
02/2016
1Pharmaceutical PreparationsIBA
05/2014
1GoldIBA
01/2014
1Nitric Oxide (Nitrogen Monoxide)FDA Link
01/2014
1Cytochrome P-450 CYP3A InhibitorsIBA
01/2013
1Member 1 Subfamily B ATP Binding Cassette TransporterIBA
01/2013
1Cytochrome P-450 CYP3AIBA
01/2013
1Verapamil (Calan)FDA LinkGeneric
01/2013
1insulin receptor-related receptor (IRR)IBA
01/2012
1SmokeIBA
11/2009
1Anti-Bacterial Agents (Antibiotics)IBA
10/2009
1Ipratropium (Ipratropium Bromide)FDA LinkGeneric
08/2008

Therapy/Procedure

9Therapeutics
10/2019 - 03/2011
1Drug Therapy (Chemotherapy)
01/2012